Related Experiment Video
Updated: Apr 8, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil
Roland E Schmieder1, Sebastian A Potthoff2, Peter Bramlage3
1Universitätsklinikum Erlangen, Medizinische Klinik 4, Schwerpunkt Nephrologie/Hypertensiologie, Erlangen, Germany.
Insights
Azilsartan medoxomil (AZL-M), an angiotensin receptor blocker, offers superior blood pressure control compared to angiotensin-converting enzyme (ACE) inhibitors in newly diagnosed hypertension patients. Both drug classes demonstrated similar safety profiles in real-world settings.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are standard first-line treatments for newly diagnosed hypertension.
- Limited real-world data exists on the comparative effectiveness and tolerability of these drug classes.
Purpose of the Study:
- To evaluate the real-world effectiveness and tolerability of azilsartan medoxomil (AZL-M) compared to ACE inhibitors in patients with newly diagnosed hypertension.
Main Methods:
- Prospective registry study (EARLY) including 1153 patients with newly diagnosed hypertension.
- Patients were prescribed either AZL-M (n=789) or an ACE inhibitor (n=364).
- Multivariate adjustment was used to analyze outcomes.
Main Results:
- AZL-M demonstrated superior blood pressure reduction compared to ACE inhibitors.
- Higher achievement of target blood pressure (<140/90 mm Hg) was observed with AZL-M.
- No statistically significant difference in the proportion of adverse events between the two groups.
Conclusions:
- Azilsartan medoxomil provides superior blood pressure control in newly diagnosed hypertensive patients.
- AZL-M exhibits a similar safety profile to ACE inhibitors in this patient population.
Abstract:
For patients with newly diagnosed hypertension, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are usually the first-line therapies. There is, however, no real-life data regarding the relative clinical effectiveness and tolerability of either drug class. The prospective registry, Treatment With Azilsartan Compared to ACE Inhibitors in Antihypertensive Therapy (EARLY), was conducted to evaluate the effectiveness of the ARB azilsartan medoxomil (AZL-M) vs ACE inhibitors in real-world patients. Of the 1153 patients with newly diagnosed hypertension who were included in the registry, 789 were prescribed AZL-M and 364 were prescribed an ACE inhibitor. After multivariate adjustment, AZL-M was found to provide superior blood pressure reduction and better target blood pressure (<140/90 mm Hg) achievement. The proportion of patients with adverse events was not statistically different between groups. The authors conclude that in newly diagnosed hypertensive patients, AZL-M provides superior blood pressure control with a similar safety profile compared with ACE inhibitors.
